The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months

Abstract

AbstractAimTo report health‐related patient‐reported outcomes (PROs) in people with type 2 diabetes (T2D) initiating their first injectable glucose‐lowering medication (GLM) with two commonly prescribed glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) from the prospective, observational TROPHIES study (The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients).Materials and MethodsTROPHIES was a two‐cohort, 24‐month study conducted in France, Germany and Italy. Adults with a T2D diagnosis, naïve to injectable treatment for T2D and prescribed dulaglutide or liraglutide as their first injectable GLM, were eligible for inclusion. Study objectives included describing the following PROs associated with the treatment of T2D with GLP‐1RAs: health‐related quality of life; impact of weight on self‐perception; life and work productivity; and patient satisfaction with treatment and injection device. Additional analyses formally compared PRO measures between the treatment cohorts.ResultsOverall, improvements from baseline in PRO scores were observed among people who started dulaglutide or liraglutide. A more pronounced trend of improvement was observed in the dulaglutide cohort for changes from baseline in treatment satisfaction and impact of weight on self‐perception, supported by statistically significant differences between treatment cohorts in additional comparative analyses at 12, 18 and 24 months. More positive patient perceptions of the injection device were observed with dulaglutide than with liraglutide.ConclusionsImprovements in PROs observed in TROPHIES, which were more evident with dulaglutide than liraglutide, reflect a relevant clinical benefit. From the patients’ perspective, satisfaction, and confidence in continuing treatment with GLP‐1RAs is likely to contribute to long‐term treatment persistence.